. Author manuscript; available in PMC: 2014 Jun 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):245–248. doi: 10.1097/QAI.0b013e31828decf8

Table 1.

HIV-1 RNA, proinflammatory cytokine concentration, hemoglobin and CD4+ cell count at enrollment and by month of follow-up (N=25)

	Enrollment	1 month	3 months	6 months	p-value^***
Log₁₀ plasma HIV-1 RNA^**	3.79 ± 1.04	4.12 ± 1.10	4.40 ± 0.84	3.87 ± 1.03	0.34
Log₁₀ endocervical HIV-1 RNA	4.26 ± 0.91	3.99 ± 0.85	4.06 ± 0.78	4.01 ± 0.94	0.55
Detectable endocervical HIV-1 RNA (>1575)	17 (68)	16 (64)	18 (72)	14 (56)	0.26
Log₁₀ CVL HIV-1 RNA	2.46 ± 0.77	2.39 ± 0.65	2.40 ± 0.65	2.47 ± 1.13	0.60
Detectable HIV-1 RNA by CVL (>60)	15 (60)	15 (60)	17 (68)	14 (56)	0.71
CD4+ cell count (cells/mm³)	617 ± 234	548 ± 214	496 ± 209	493 ± 196	<0.001
Hemoglobin (g/dL)	12.81 ± 1.80	12.82^* ± 1.65	13.00 ± 1.92	13.20 ± 1.45	0.16
Anemia^†	7 (25)	7 (29)^*	6 (24)	4 (17)^*	0.50
Log₁₀ IL-1β	1.53 ± 0.73	1.88 ± 0.85	1.84 ± 0.68	2.05 ± 0.93	0.02
Log₁₀ IL-8	3.07 ± 0.63	3.12 ± 0.60	3.09 ± 0.53	3.29 ± 0.57	0.08
Log₁₀ SLPI	5.55 ± 0.54	5.08 ± 0.45	5.30 ± 0.45	5.53 ± 0.45^*	0.85

Result are displayed as mean ± standard deviation or N (%)

N=24

^**

Excludes samples that were inhibited or partially inhibited (N at enrollment = 19; N at 1 month = 15; N at 3 months = 18; N at 6 months =18).

^***

Compares enrollment value to the value at the 6 month follow-up visit; Wilcoxon sign rank test used for continuous outcomes and McNemar’s test used for categorical outcomes.

^†

Hemoglobin <12.0 (g/dL)